2.16
In 8 Bio Inc stock is traded at $2.16, with a volume of 129.38K.
It is down -0.92% in the last 24 hours and down -50.31% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.18
Open:
$2.2
24h Volume:
129.38K
Relative Volume:
0.95
Market Cap:
$9.92M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.88
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+1.41%
1M Performance:
-50.31%
6M Performance:
-71.70%
1Y Performance:
-91.81%
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INAB
In 8 Bio Inc
|
2.16 | 9.92M | 0 | -31.88M | -25.20M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-18-24 | Initiated | Laidlaw | Buy |
Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Quantisnow
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewswire Inc.
European Launch: TELA Bio's Natural Hernia Repair Device Shows 98.8% Success Rate - Stock Titan
TELA Bio Appoints Jeffrey Blizard as President - GlobeNewswire
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis - GlobeNewswire
Global Immunoprecipitation Market Set to Grow at a CAGR of 6-8%: Key Drivers and Challenges by 2029 - PharmiWeb.com
DNA Polymerase Market to Grow at 6–8% CAGR Driven by Genomics, PCR, and CRISPR Technologies by 2029 - PharmiWeb.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
Caisse Française de Financement Local: EMTN 2025-8 SOCIAL - The Manila Times
Protagenic Therapeutics Completes Acquisition of Phytanix Bio - TipRanks
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
KALA BIO: Q1 Earnings Snapshot - The Washington Post
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Raymond James Financial Inc. Takes Position in 8×8, Inc. (NASDAQ:EGHT) - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Call Transcript - Insider Monkey
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - GlobeNewswire
TELA Bio, Inc. (NASDAQ:TELA) Q1 2025 Earnings Call Transcript - Insider Monkey
8 Best Medical Simulators On Steam, Ranked - Game Rant
Nuvation Bio Inc. (NUVB): Among Billionaire David Abrams’ Stock Picks with Huge Upside Potential - Yahoo Finance
bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update - Yahoo Finance
TELA Bio Reports First Quarter 2025 Financial Results - Yahoo Finance
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
TELA Bio Inc (TELA) Q1 2025 Earnings Report Preview: What to Expect - Yahoo Finance
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
TELA Bio Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Instil Bio Inc expected to post a loss of $2.59 a shareEarnings Preview - TradingView
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewswire
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - The Manila Times
Gritstone bio, Inc. (GRTS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Nuvation Bio CFO to Share Latest Oncology Strategy at Exclusive Citizens Conference Next Week - Stock Titan
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and - GlobeNewswire
Phase 1a trial for THN391 yields positive results - Ophthalmology Times
Annovis Bio Appoints Hui Liu as Director of Biostatistics - GlobeNewswire
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting - Yahoo Finance
Cerity Partners LLC Makes New Investment in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Tevogen Bio Announces 2025 Annual Meeting - GlobeNewswire
TELA Bio to Announce Q1 2025 Earnings on May 8 - MSN
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
In 8 Bio Inc Stock (INAB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
McCall Patrick | CHIEF FINANCIAL OFFICER |
Apr 30 '25 |
Option Exercise |
0.18 |
15,000 |
2,766 |
67,071 |
Roemer Alan S. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
113,459 |
20,922 |
398,489 |
Brandt Peter C. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
163,934 |
30,229 |
681,538 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):